STOCK TITAN

Harrow Health to Announce First Quarter 2021 Financial Results on May 11, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

NASHVILLE, Tenn., April 27, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the first quarter ended March 31, 2021, on Tuesday, May 11, 2021, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.

Conference Call Details: 
Date:Tuesday, May 11, 2021
Time:4:45 p.m. Eastern time
Participant Dial-in:1-877-270-2148 (U.S.)
1-412-902-6510 (International)
Replay Dial-in (Passcode 10153709):
(telephonic replay through May 18, 2021)
1-877-344-7529 (U.S.)
1-412-317-0088 (International)
Webcast: (online replay through August 11, 2021)harrowinc.com

About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) is an ophthalmic-focused healthcare company. The Company owns ImprimisRx, the nation’s leading ophthalmology outsourcing and pharmaceutical compounding business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Contact:
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737


Harrow, Inc.

NASDAQ:HROW

HROW Rankings

HROW Latest News

HROW Stock Data

364.08M
26.55M
14.59%
66.11%
17.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NASHVILLE

About HROW

harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas